These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23832923)

  • 41. [Would the developed countries need catalogs for essential medicines?].
    Vuorenkoski L
    Duodecim; 2005; 121(14):1495-6. PubMed ID: 16209312
    [No Abstract]   [Full Text] [Related]  

  • 42. The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member.
    Krenzelok EP
    Clin Toxicol (Phila); 2009 Sep; 47(8):784-9. PubMed ID: 19735211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA prohibits extralabel use of two drug classes.
    J Am Vet Med Assoc; 1997 Aug; 211(3):269. PubMed ID: 9262656
    [No Abstract]   [Full Text] [Related]  

  • 44. Over-the-counter analgesics in older adults: a call for improved labelling and consumer education.
    Roumie CL; Griffin MR
    Drugs Aging; 2004; 21(8):485-98. PubMed ID: 15182214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication.
    Bradford WD; Kleit AN
    Health Econ; 2015 Jul; 24(7):859-75. PubMed ID: 25059655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proposed US Food and Drug Administration guidance for industry on distributing medical publications about the risks of prescription drugs and biological products: a misguided approach.
    Wolfe SM
    JAMA Intern Med; 2014 Oct; 174(10):1543-4. PubMed ID: 25127222
    [No Abstract]   [Full Text] [Related]  

  • 47. Conservative use of prescription drugs: comment on "Communicating uncertainties about prescription drugs to the public".
    Grady D
    Arch Intern Med; 2011 Sep; 171(16):1470. PubMed ID: 21911631
    [No Abstract]   [Full Text] [Related]  

  • 48. Impact of implementing alerts about medication black-box warnings in electronic health records.
    Yu DT; Seger DL; Lasser KE; Karson AS; Fiskio JM; Seger AC; Bates DW
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):192-202. PubMed ID: 21254291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An interview with FDA commissioner Hayes.
    Small WE
    Am Pharm; 1981 Oct; NS21(10):27-36. PubMed ID: 6803557
    [No Abstract]   [Full Text] [Related]  

  • 50. "Use as Directed" Can Cause Confusion for Both Patients and Practitioners.
    Shastay A
    Home Healthc Now; 2018; 36(2):128-130. PubMed ID: 29498995
    [No Abstract]   [Full Text] [Related]  

  • 51. FDA response to droperidol black box warning editorials.
    Rappaport BA
    Anesth Analg; 2008 May; 106(5):1585. PubMed ID: 18420886
    [No Abstract]   [Full Text] [Related]  

  • 52. Pro: The Food and Drug Administration Black box warning on droperidol is not justified.
    Habib AS; Gan TJ
    Anesth Analg; 2008 May; 106(5):1414-7. PubMed ID: 18420854
    [No Abstract]   [Full Text] [Related]  

  • 53. Drug labelling and a near miss in the labour suite.
    Murdoch JA; Lane J; Goldstein DH
    Can J Anaesth; 2004 Oct; 51(8):854-5. PubMed ID: 15470184
    [No Abstract]   [Full Text] [Related]  

  • 54. Con: The black box warning on droperidol should not be removed (but should be clarified!).
    Ludwin DB; Shafer SL
    Anesth Analg; 2008 May; 106(5):1418-20. PubMed ID: 18420855
    [No Abstract]   [Full Text] [Related]  

  • 55. What does it mean when a drug has a black box warning?
    Mayo Clin Womens Healthsource; 2005 Jul; 9(7):10. PubMed ID: 16015214
    [No Abstract]   [Full Text] [Related]  

  • 56. Trademark attorneys enlist pharmacists in the battle to prevent medication errors.
    Di Domizio G
    Hosp Pharm; 1995 Jan; 30(1):47-51. PubMed ID: 10184257
    [No Abstract]   [Full Text] [Related]  

  • 57. Characteristics of container labeling in a sample of commonly prescribed children's oral medications.
    Wallace LS; Keenum AJ; DeVoe JE
    Res Social Adm Pharm; 2010 Dec; 6(4):272-9. PubMed ID: 21111385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. From physician intent to the pharmacy label: prevalence and description of discrepancies from a cross-sectional evaluation of electronic prescriptions.
    Cochran GL; Klepser DG; Morien M; Lomelin D; Schainost R; Lander L
    BMJ Qual Saf; 2014 Mar; 23(3):223-30. PubMed ID: 24106311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bringing greater transparency to "black box" warnings.
    Buckley NA; Rossi S
    Clin Toxicol (Phila); 2011 Jul; 49(6):448-51. PubMed ID: 21824055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.